2026-04-25T21:31:25Z
https://www.pub.unibl.org/oai
oai:pub.unibl.org:29311
2026-03-26T04:43:28Z
Bevacizumab in Combination with Irinotecanand Capecitabine as First-Line Treatment for MCRC - Efficacy and Safety (Meeting Abstract)
/unibl/author/Saša Jungić
/unibl/author/Gordana Kecman Malčić
/unibl/author/Ivanka Rakita
/unibl/author/Dušan Jovanović
/unibl/author/Radoslav Gajanin
/unibl/author/Zdravko Marić
/unibl/author/Zdenka Gojković
https://www.unibl.org/sr-lat/fis/zaposlen/3255-biljana-tubic
2014
Conference Paper
text
68
68
/unibl/sci/idNaucniRad:13157
https://dx.doi.org/doi: 10.1093/annonc/mdu165.175
This article appears in:ESMO 16th World Congress on Gastrointestinal Cancer, 25–28 June 2014, Barcelona, Spain
Annals of Oncology, Vol. 25(2)
Annals of Oncology, Vol. 25(2)
http://annonc.oxfordjournals.org/content/25/suppl_2/ii68.3.full
S. Jungić, G. Kecman Malčić, I. Rakita, D. Jovanović, R. Gajanin, Z. Marić, Z. Gojković, B. Tubić, Bevacizumab in Combination with Irinotecanand Capecitabine as First-Line Treatment for MCRC - Efficacy and Safety (Meeting Abstract), Annals of Oncology, Vol. 25(2), pp. 68 - 68, 2014